

macologic effects. *Br J Clin Pharmacol.* 2018;84(11):2468-2476.

46. Amendola G, Bocca B, Picardo V, et al. Toxicological aspects of cannabinoid, pesticide and metal levels detected in light Cannabis inflorescences grown in Italy. *Food Chem Toxicol.* 2021;156:112447.

47. Taylor A, Birkett JW. Pesticides in cannabis: A review of analytical and toxicological considerations. *Drug Test Anal.* 2020;12(2):180-190.

48. Volkow ND, Weiss SRB. Importance of a standard unit dose for cannabis research. *Addiction.* 2020;115(7): 1219-1221.

49. McDonagh MS, Morasco BJ, Wagner J, et al. Cannabis-Based Products for Chronic Pain : A Systematic Review. *Ann Intern Med.* 2022;175(8):1143-1153.

50. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA.* 2015;313(24):2456-2473.

51. Boehnke KF, Gangopadhyay S, Clauw DJ, et al. Qualifying Conditions Of Medical Cannabis License Holders In The United States. *Health Aff (Millwood).* 2019;38(2):295-302.

52. Slawek DE, Curtis SA, Arnsten JH, et al. Clinical Approaches to Cannabis: A Narrative Review. *Med Clin North Am.* 2022;106(1):131-152.

53. Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). *CNS Neurosci Ther.* 2009;15(1):84-88.

54. Jetly R, Heber A, Fraser G, et al. The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: A preliminary randomized, double-blind, placebo-controlled cross-over design study. *Psychoneuroendocrinology.* 2015;51:585-588.

55. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress

disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. *J Clin Psychopharmacol.* 2014;34(5):559-564.

56. Doppen M, Kung S, Majiers I, et al. Cannabis in Palliative Care: A Systematic Review of Current Evidence. *J Pain Symptom Manage.* 2022;64(5):e260-284.

57. MacDonald E, Farrah K. Medical Cannabis Use in Palliative Care: Review of Clinical Effectiveness and Guidelines – An Update [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019. cit. 29-11-2024. (CADTH Rapid Response Reports). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK551867/>.

58. Hammond S, Erridge S, Mangal N, et al. The Effect of Cannabis-Based Medicine in the Treatment of Cachexia: A Systematic Review and Meta-Analysis. *Cannabis Cannabinoid Res.* 2021;6(6):474-487.